Immunoclassification of Psoriasis: a Strategy for Precision Medicine
- Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Study ID
- NCT05503875
- Status
- Recruiting
Conditions
- Immunoclassification
- Psoriasis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 75 Years
- Healthy Volunteers
- Accepted
Interventions
- adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors, methotrexate — BIOLOGICALPsoriasis patients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
Study Details
Through the combination of clinical manifestations and omics, the investigators aim to explore the skin cell atlas in different stages of psoriasis lesions, establish a clinical classification standard for psoriasis, and guide the precise treatment of psoriasis.
Key Dates
- Start date
- Jan 1, 2023
- Status verified
- Jan 2024
- Primary completion
- Dec 31, 2027
- Completion
- Dec 31, 2027
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: treatmentPatients will be treated with adalimumab, secukinumab, ixekizumab, guselkumab, Jak inhibitors or methotrexate.
Primary Outcome Measure
Differences in the number of immune cells (dendritic cells, macrophages) in the lesional skin, non-lesional skin of psoriasis patients and healthy skin. [ Time Frame: 16 months ]
Central Contacts
- Xiao-yong Man13600516219
Related Studies
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- Regulation of Inflammatory Genes in PsoriasisRecruiting · University of Alabama at Birmingham · Birmingham, Alabama
- LTS of Siliq vs. Other Therapies Treating of Adults With Moderate-to-Severe PsoriasisEnrolling By Invitation · Bausch Health Americas, Inc. · Bridgewater, New Jersey
- An Open-Label, Pilot Study to Evaluate the Efficacy of Narrowband Ultraviolet-B Phototherapy Three Times Weekly for Twelve Weeks in Moderate-to-Severe Psoriasis PatientsRecruiting · Psoriasis Treatment Center of Central New Jersey · East Windsor, New Jersey